Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines
A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae.
1 - 12 . (canceled)
13 . A method for treating or controlling an inflammatory ocular disease, condition, or disorder, the method comprising administering a composition that comprises levocabastine, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, in an amount and at a frequency effective to treat or control said disease, condition, or disorder, to a portion of an eye of a subject in need of such treatment or control.
14 . The method of claim 13 , wherein said inflammatory disease, condition, or disorder is selected from the group consisting of dry eye, anterior uveitis, iritis, iridocyclitis, keratitis, conjunctivitis, keratoconjunctivitis, vernal keratoconjunctivitis (“VKC”), atopic keratoconjunctivitis, corneal ulcer, corneal edema, sterile corneal infiltrates, anterior scleritis, episcleritis, blepharitis, and post-operative (or post-surgical) ocular inflammation resulting from photorefractive keratectomy, cataract removal surgery, intraocular lens (“IOL”) implantation, laser-assisted in situ keratomileusis (“LASIK”), conductive keratoplasty, or radial keratotomy, and combinations thereof.
15 . The method of claim 13 , wherein said inflammatory disease, condition, or disorder is selected from the group consisting of diabetic retinopathy (“DR”), age-related macular degeneration (“AMD,” including dry and wet AMD), diabetic macular edema (“DME”), posterior uveitis, optic neuritis, inflammatory optic neuropathy, optic neuropathy caused by glaucoma, and combinations thereof.
16 . The method of claim 13 , wherein said inflammatory disease, condition, or disorder comprises inflammatory sequelae of an infection.
17 . The method of claim 16 , wherein said inflammatory sequelae comprise chronic inflammation of the anterior or posterior segment of an eye.
18 . The method of claim 13 , wherein the composition further comprises an additional H 1 -receptor antagonist.
19 . The method of claim 13 , wherein the composition further comprises a material selected from the group consisting of anti-infective agents, anti-inflammatory agents other than H 1 -receptor antagonists, immunosuppressive agents, and combinations thereof
20 - 24 . (canceled)